{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:33:21Z","timestamp":1778153601605,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.leukres.2010.03.033","type":"journal-article","created":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T08:51:11Z","timestamp":1272703871000},"page":"1459-1471","source":"Crossref","is-referenced-by-count":33,"title":["Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era"],"prefix":"10.1016","volume":"34","author":[{"given":"Dong-Wook","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shripad D.","family":"Banavali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udomsak","family":"Bunworasate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeow-Tee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ganly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Irving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saengsuree","family":"Jootar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Gyung","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-Piu","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Chin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Visalachy","family":"Purushotaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harryanto","family":"Reksodiputro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee-Yung","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jih-Luh","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arinobu","family":"Tojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.03.033_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12185-008-0230-0","article-title":"Chronic myeloid leukemia in Asia","volume":"89","author":"Wing","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2010.03.033_bib2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.03.033_bib3","unstructured":"Guilhot F, Larson R, O\u2019Brien S, Druker B, on behalf of IRIS Study Group. Long-term benefits of imatinib for patients newly diagnosed with chronic myeloid leukemia in chronic phase: the 5-year update from the IRIS study. Haematologica 2006;91:170 [Abstract 466]."},{"key":"10.1016\/j.leukres.2010.03.033_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3747\/co.v13i6.124","article-title":"Recommendations of the Canadian consensus group on the management of chronic myeloid leukemia","volume":"13","author":"Laneuville","year":"2006","journal-title":"Curr Oncol"},{"key":"10.1016\/j.leukres.2010.03.033_bib5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.03.033_bib6","series-title":"Chronic myelogenous leukemia. Version 2","author":"National Comprehensive Cancer Network","year":"2007"},{"key":"10.1016\/j.leukres.2010.03.033_bib7","unstructured":"Grigg A, Hughes T; for the Australasian Leukemia and Lymphoma Group (ALLG) Myoproliferative Disease Subcommittee. Australasian treatment guidelines for de novo CML CP, v1.0. Canterbury Health Laboratories, Christchurch, New Zealand, 2006."},{"key":"10.1016\/j.leukres.2010.03.033_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.03.033_bib9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.03.033_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0041-1733114","article-title":"Therapy with imatinib for chronic myeloid leukaemia","volume":"26","author":"Arora","year":"2005","journal-title":"Ind J Med Paediatr Oncol"},{"key":"10.1016\/j.leukres.2010.03.033_bib11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/cncr.22498","article-title":"Treatment of chronic myeloid leukemia in the imatinib era perspective from a developing country","volume":"109","author":"Aziz","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.03.033_bib12","first-page":"281","article-title":"Treatment of 54 chronic myelogenous leukaemia with Glivec","volume":"24","author":"Jiang","year":"2003","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.leukres.2010.03.033_bib13","first-page":"255","article-title":"Chronic myelogenous leukaemia (CML): an update","volume":"19","author":"Kumar","year":"2006","journal-title":"Natl Med J India"},{"key":"10.1016\/j.leukres.2010.03.033_bib14","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL positive leukemias treated with imatinib in a single center: a 4.5 years follow up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.03.033_bib15","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.03.033_bib16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12185-009-0292-7","article-title":"Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population","volume":"89","author":"Zhao","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2010.03.033_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3810\/pgm.1999.09.686","article-title":"Chronic myelogenous leukemia. Curable with early diagnosis and treatment","volume":"106","author":"Hill","year":"1999","journal-title":"Postgrad Med"},{"key":"10.1016\/j.leukres.2010.03.033_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.leukres.2010.03.033_bib19","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1186\/1752-1947-3-7112","article-title":"Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report","volume":"29","author":"Goubran","year":"2009","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.leukres.2010.03.033_bib20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12185-009-0326-1","article-title":"Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia","volume":"89","author":"Kim","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2010.03.033_bib21","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/cncr.22523","article-title":"Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns","volume":"109","author":"Kantarajian","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.03.033_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.03.033_bib23","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1080\/10428190902926973","article-title":"Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy","volume":"50","author":"Goh","year":"2009","journal-title":"Leuk Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610001748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610001748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:26:30Z","timestamp":1685579190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610001748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0145212610001748"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.03.033","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}